Introducing: Altitude Capital Partners

By: Ian McClure
altitude

I would introduce the purpose and activities of Altitude Capital Partners myself, but an Amicus brief filed by Altitude Capital Partners (along with Ocean Tomo, Inflexion Point Strategy, IPotential, and others) with the U.S. Supreme Court in KSR International Co., v. Teleflex, Inc., introduces Altitude better than any summary I could come up with.  Therefore, Altitude Capital Partners invests in patents as well as the firms that own them. By specializing in the valuation and enforcement of intellectual property rights, Altitude serves, as one ... Read More

Categories: IP Market Players

Introducing: Ocean Tomo

By: Ian McClure
ocean20tomo

A first-mover and current trend-setter in the intellectual property management and valuation fields, Ocean Tomo is changing the way the world looks at IP.  First started in 1987 as a firm that provided IP valuation opinions, Ocean Tomo is now the nation's first intellectual capital merchant banc with a large bag of services.  The company provides expert testimony services, IP valuation services, IP investment services, as well as general counsel and assistance related to any IP transactions.  However, none of these, in my ... Read More

Categories: IP Market Players

Introducing: PatentFreedom

By: Ian McClure
liberty-bell

 PatentFreedom is a full service establishment offering subscription-based assistance in fighting the threat of non-practicing entities (NPE's).  NPE's are a growing threat to operating companies with patent portfolios of their own, in that NPE's don't hold their patents for core operational purposes, but instead use strategic enforcement activities such as licensing and litigation to turn a profit.  This use of patents has grown into a threatening phenomenon in the technology industries at an alarming rate.  PatentFreedom sets out to educate operating companies ... Read More

Categories: IP Market Players

Introducing: Royalty Pharma

By: Ian McClure
pharma20

This week's IP Market Player is Royalty Pharma.  The name has begun to pop up in articles and conversations regarding attractive alternatives to raising equity capital. In a nutshell, the company purchases royalty interests in biopharmaceutical products and late-stage development drugs.  Through careful purchases, it provides liquidity to its shareholders investing in these royalty streams while assuming the risks of ownership in this IP.  This is an innovative product driven method of financing that is somewhat shielded from market volatility and stock price ... Read More

Categories: IP Market Players